Ninjurin 2 rs118050317 gene polymorphism and endometrial cancer risk.
Clinical index
Endometrial cancer
Ninjurin2
Single nucleotide polymorphisms
Journal
Cancer cell international
ISSN: 1475-2867
Titre abrégé: Cancer Cell Int
Pays: England
ID NLM: 101139795
Informations de publication
Date de publication:
04 Jan 2021
04 Jan 2021
Historique:
received:
09
06
2020
accepted:
09
11
2020
entrez:
5
1
2021
pubmed:
6
1
2021
medline:
6
1
2021
Statut:
epublish
Résumé
Endometrial cancer is one of the most common female reproductive system tumors. Ninjurin2 (NINJ2) is a new adhesion factor. As a vascular susceptibility gene, it is highly expressed in other cancers and promotes the growth of cancer cells. We conducted an association analysis between NINJ2 gene polymorphism and endometrial cancer risk. Five SNPs rs118050317, rs75750647, rs7307242, rs10849390 and rs11610368 of NINJ2 gene were genotyped in 351 endometrial cancer patients and 344 healthy controls. The clinical index difference between cases and controls were tested by one-way analysis of variance. The allele and genotype frequency of cases and controls were been compared by Chi square test. The odds ratios (OR) with 95% confidence interval (95% CI) were examined by logistic regression analysis. The SNP rs118050317 mutant allele C and homozygote CC genotype were significant increased the endometrial cancer risk (OR 1.46, 95% CI 1.04-2.06, p = 0.028; OR 8.43, 95% CI 1.05-67.89, p = 0.045). In the clinical index analysis, there were significant higher quantities of CEA, CA125 and AFP in cases serum than controls. The NINJ2 gene polymorphism loci rs118050317 mutant allele C was associated with an increased risk of endometrial cancer. CEA, CA125 and AFP quantities were significant higher in endometrial cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
Endometrial cancer is one of the most common female reproductive system tumors. Ninjurin2 (NINJ2) is a new adhesion factor. As a vascular susceptibility gene, it is highly expressed in other cancers and promotes the growth of cancer cells. We conducted an association analysis between NINJ2 gene polymorphism and endometrial cancer risk.
METHODS
METHODS
Five SNPs rs118050317, rs75750647, rs7307242, rs10849390 and rs11610368 of NINJ2 gene were genotyped in 351 endometrial cancer patients and 344 healthy controls. The clinical index difference between cases and controls were tested by one-way analysis of variance. The allele and genotype frequency of cases and controls were been compared by Chi square test. The odds ratios (OR) with 95% confidence interval (95% CI) were examined by logistic regression analysis.
RESULTS
RESULTS
The SNP rs118050317 mutant allele C and homozygote CC genotype were significant increased the endometrial cancer risk (OR 1.46, 95% CI 1.04-2.06, p = 0.028; OR 8.43, 95% CI 1.05-67.89, p = 0.045). In the clinical index analysis, there were significant higher quantities of CEA, CA125 and AFP in cases serum than controls.
CONCLUSION
CONCLUSIONS
The NINJ2 gene polymorphism loci rs118050317 mutant allele C was associated with an increased risk of endometrial cancer. CEA, CA125 and AFP quantities were significant higher in endometrial cancer patients.
Identifiants
pubmed: 33397383
doi: 10.1186/s12935-020-01646-5
pii: 10.1186/s12935-020-01646-5
pmc: PMC7784262
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1Références
Medicine (Baltimore). 2018 Jun;97(23):e10863
pubmed: 29879020
J Neurosci. 2000 Jan 1;20(1):187-95
pubmed: 10627596
Biochem Biophys Res Commun. 2014 Mar 28;446(1):167-72
pubmed: 24582558
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
PLoS One. 2011;6(6):e20573
pubmed: 21674003
Zhonghua Bing Li Xue Za Zhi. 2014 Oct;43(10):649-50
pubmed: 25567588
Cancer Biomark. 2010;6(2):63-72
pubmed: 20571232
Nat Genet. 2011 May;43(5):451-4
pubmed: 21499250
Nat Genet. 2016 Jun;48(6):667-674
pubmed: 27135401
Mol Neurobiol. 2016 Dec;53(10):7178-7183
pubmed: 26687183
J Biomed Res. 2011 Jul;25(4):287-91
pubmed: 23554703
Lancet. 2005 Aug 6-12;366(9484):491-505
pubmed: 16084259
Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):216-23
pubmed: 23221126
Cancer Epidemiol. 2012 Jun;36(3):283-7
pubmed: 22369735
Cancer Epidemiol. 2012 Dec;36(6):e366-72
pubmed: 22796266
Am J Hum Genet. 2016 Jun 2;98(6):1159-1169
pubmed: 27259051
Hum Genet. 2014 Feb;133(2):211-24
pubmed: 24096698
Eur J Obstet Gynecol Reprod Biol. 2017 Nov;218:113-118
pubmed: 28964972
Menopause. 2016 Aug;23(8):884-7
pubmed: 27272224
J Thromb Thrombolysis. 2014 Nov;38(4):470-6
pubmed: 24664524
Int J Cancer. 2017 Feb 1;140(3):600-610
pubmed: 27770434
Cell Signal. 2017 Jul;35:231-241
pubmed: 28431986
J Intern Med. 2020 Aug;288(2):207-218
pubmed: 32372544
Oncol Rep. 2013 Jul;30(1):25-34
pubmed: 23624782
Obstet Gynecol. 2015 Jan;125(1):89-98
pubmed: 25560109
Biochem Biophys Res Commun. 2009 Sep 18;387(2):321-5
pubmed: 19595672
Pathol Oncol Res. 2016 Jan;22(1):135-8
pubmed: 26386690